Compositions and methods for the treatment of glaucoma and other ocular
diseases are disclosed. The compositions and methods are particularly
directed to the use inhibitors of Jun N-terminal kinases (JNK), such as
SP600125 in the treatment of glaucoma and other ocular diseases.